Michiel Van der Heijdan explores the role of radiotherapy and other neoadjuvant combinations to prevent the need for surgery in patients with muscle-invasive bladder cancer.
Dr. Van der Heijdan serves as research group leader at the Netherlands Cancer Institute, and has contributed research to the EV-302 and NABUCCO studies.